What compels a dentist who has been grafting for decades to change course and spend 12 years exploring the potential of a single product line? For Dr. Charles Schlesinger, the answer involves unincorporated particulate, impatient patients, and a question: Is your product sintered?
In this sponsored episode of The DrBicuspid.com Podcast, Editor-in-Chief Kevin Henry sits down with Dr. Schlesinger -- a 30-year general dentist and now clinical vice president for Solmetex and Impladent -- for a candid conversation about bone grafting, the future of implant dentistry, and why the OsteoGen family of products has become the cornerstone of his clinical approach.
Schlesinger brings a perspective that goes beyond product endorsement. He traces his evolution as a clinician -- from xenograft to allograft to OsteoGen -- explaining the clinical reasoning behind each shift and what he saw in the operatory that drove him to seek out a better solution.
What's covered in the podcast:
- Why residency-trained dentists often start with xenograft and the clinical problems that can follow
- What "sintered" means and why it matters for how quickly the body can break down a graft material
- Why bovine bone can take seven to eight months or longer to resorb and what that means for implant timelines
- The handling advantages of a collagen-bound plug versus particulate material
- Why non-sintered calcium phosphate gives the body the raw materials it needs to regenerate bone naturally
- The full range of uses for OsteoGen beyond socket preservation: vertical and horizontal sinus lifting, ridge augmentation, defect repair, and grafting around immediate implants
- Where implant dentistry is headed -- biomimetic materials, improved thread forms, faster integration -- and how grafting philosophy fits into that shift
- Why Schlesinger calls Osteogen "a simple product that is very advanced in many ways"
This episode is sponsored by Impladent.
